This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.
Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.
Taxability of earnings:
|S&P BSE Healthcare TRI||-1.67||-0.50||0.52||2.02||--||--||--||--||--||--||--|
|Rank within category||1||4||1||5||--||--||--||--||--||--||--|
|Number of funds in category||14||14||14||14||12||12||9||7||4||3||3|
As on 17-Jan-2022
|Fund name||Rating||Launch Date||1-Year Return||3-Year Return||5-Year Return||Expense Ratio||Assets (Cr)|
|ITI Pharma and Healthcare Fund - Regular Plan||Nov-21||--||--||--||2.61%||179|
|Nippon India Pharma Fund||Jun-04||17.60||25.99||17.91||1.95%||5,397|
|ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund | Invest Now||Jul-18||14.57||27.46||--||2.13%||2,964|
|SBI Healthcare Opportunities Fund | Invest Online||Jul-99||14.63||23.76||11.85||2.10%||1,943|
|Mirae Asset Healthcare Fund - Regular Plan | Invest Online||Jul-18||24.50||31.53||--||2.06%||1,935|
|Best Performance||Worst Performance|
|Return (%)||Period||Return (%)||Period|
|Week||4.82||24-Dec-2021 - 31-Dec-2021||-2.67||14-Dec-2021 - 21-Dec-2021|
|Month||5.09||06-Dec-2021 - 05-Jan-2022||-3.14||18-Nov-2021 - 20-Dec-2021|
|S&P BSE Healthcare TRI*||24.04||21.45||0.95||1.89||--||--|
|Rank within category||--||--||--||--||--||--|
|Number of funds in category||--||--||--||--||--||--|
The Risk Measures have been calculated using calendar month returns for the last three years.
* As on 31-Dec-2021
|Number of Stocks||25|
|Top 10 Stocks (%)||69.43|
|Top 5 Stocks (%)||48.23|
|Top 3 Sectors (%)||89.40|
|Portfolio P/B Ratio||4.59|
|Portfolio P/E Ratio||32.88|
|Average Mkt Cap (Rs Cr)||49,693||57,163|
|Company||Sector||P/E||3Y High||3Y Low||% Assets|
|Sun Pharmaceutical Industries||Healthcare||32.82||17.66||16.85||17.66|
|Dr. Reddy's Lab||Healthcare||39.65||9.91||9.72||9.72|
|Max Financial Services||Financial||117.75||2.02||1.97||1.97|
|SBI Life Insurance Company||Insurance||102.87||1.93||1.04||1.93|
|ICICI Lombard General Insurance Company||Insurance||55.62||1.33||0.94||1.33|
|Aster DM Healthcare||Healthcare||26.97||1.28||0.93||1.28|
|JB Chemicals & Pharma||Healthcare||28.42||1.08||0.00||1.08|
|Max Healthcare Institute||Healthcare||84.57||0.75||0.69||0.75|
Indicates an increase or decrease or no change in holding since last portfolio
Indicates a new holding since last portfolio
As on 31-Dec-2021
Education: Mr Pradeep is a qualified Chartered Accountant from Institute of Chartered Accountants of India, New Delhi and a Chartered Financial Analyst from CFA Institute – USA.
Experience: Prior to joining ITI Asset Management Ltd., he has worked with Tata Asset Management Ltd., CARE Ratings Ltd., Bombay Dyeing, Tata International and Lubrizol India Ltd. He has over 23 years of extensive experience in Fund Management, Equity Research, Credit Evaluation and Ratings. During his 15-year stint at Tata Asset Management Ltd., he managed a broad spectrum of schemes across large cap (Tata Large Cap Fund), multi cap (Tata Large and Midcap Fund, Tata India Tax Savings Fund and the equity portion of Tata Hybrid Equity Fund), offshore fund (Tata India Offshore Opportunities Fund) and thematic funds (Tata Ethical Fund) with assets under management exceeding Rs. 5,000 crores. He was responsible for heading the equity research function and also for tracking various sectors and a wide variety of stocks. On the other hand, at CARE, he took care of multiple ratings and advisory assignments of companies across manufacturing, financial services and other services sectors.
Education: Mr. Korde is a Masters in Management Studies (Finance), Bachelor of Commerce
Experience: Prior to joining Asset Management Limited, he has worked with BOB Capital Markets as Vice President Research, Prabhudas Lilladher as Vice President Research and Anand Rathi Share & Stock Brokers as Vice President Research.
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
|Min. Investment (₹)||5,000|
|Min. Addl Investment (₹)||1,000|
|Min. SIP Investment (₹)||500|
|Min. No of Cheques||12|
|Min. Withdrawal (₹)||1,000|
|Min. Balance (₹)||--|
|Lock-in Period||Not Applicable|
|Exit Load||1% for redemption within 365 days|
|Fund House:||ITI Mutual Fund|
|Return Since Launch:||2.08%|
|Benchmark:||NIFTY Healthcare TRI.|
|Assets:||₹ 179 Cr (As on 31-Dec-2021)|
|Expense:||2.61% (As on 30-Nov-2021)|
AMC: ITI Asset Management Ltd.
Address: ITI Asset Mangement Limited, ITI House, Building no. 36, Dr. R. K. Shirodkar Marg, Parel, Mumbai - 400012
Phone: 1800-266-9603 / 022-66214999
Email: [email protected]
Registrar & Transfer Agent: KFin Technologies Pvt Ltd.
Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016
Email: [email protected]